Department of Clinical Medicine, School of Medicine, Zhejiang University City College, Hangzhou 310015, China.
Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai 200032, China.
Viruses. 2022 Feb 14;14(2):387. doi: 10.3390/v14020387.
Several countries have made unremitting efforts to develop an optimal vaccine in the fight against coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With the increasing occurrence of SARS-CoV-2 variants, current vaccines show decreased neutralizing activities, especially towards the Omicron variant. In this context, adding appropriate adjuvants to COVID-19 vaccines can substantially reduce the number of required doses and improve efficacy or cross-neutralizing protection. We mainly focus on research progress and achievements associated with adjuvanted COVID-19 subunit and inactivated vaccines. We further compare the advantages and disadvantages of different adjuvant formulations in order to provide a scientific reference for designing an effective strategy for future vaccine development.
为应对由严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）引起的 2019 年冠状病毒病（COVID-19），一些国家一直在不懈努力研发最佳疫苗。随着 SARS-CoV-2 变异株的不断出现，目前的疫苗显示出中和活性降低，尤其是针对奥密克戎变异株。在此背景下，在 COVID-19 疫苗中添加适当的佐剂可以显著减少所需剂量，并提高疗效或交叉中和保护作用。我们主要关注与佐剂 COVID-19 亚单位和灭活疫苗相关的研究进展和成果。我们进一步比较了不同佐剂配方的优缺点，以期为未来疫苗开发的有效策略设计提供科学参考。
